(Q36577320)

15 August 2017

1 reference

title

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease (English)

1 reference

15 August 2017

1 reference

1 reference

Fabrizio Stocchi

3

0 references

Charles Warren Olanow

series ordinal

1

object named as

C Warren Olanow

1 reference

15 August 2017

José A Obeso

2

1 reference

15 August 2017

publication date

1 July 2006

1 reference

Nature Clinical Practice Neurology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

7

1 reference

15 August 2017

page(s)

382-392

1 reference

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

The scientific basis for the current treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Levodopa motor complications in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Parkinson's disease. First of two parts

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Continuous dopamine-receptor stimulation in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

The control of firing pattern in nigral dopamine neurons: single spike firing

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Real-time decoding of dopamine concentration changes in the caudate?putamen during tonic and phasic firing

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Young-onset Parkinson's disease: a clinical review

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Young onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

The functional anatomy of basal ganglia disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Primate models of movement disorders of basal ganglia origin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Pathophysiology of the basal ganglia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Direct receptor cross-talk can mediate the modulation of excitatory and inhibitory neurotransmission by dopamine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Predictive reward signal of dopamine neurons

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Unilateral dopamine denervation blocks corticostriatal LTP

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Continuous and intermittent levodopa differentially affect basal ganglia function

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

JEJUNAL DELIVERY OF LEVODOPA METHYL ESTER

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

A controlled trial of rotigotine monotherapy in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Transdermal lisuride delivery in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Apomorphine tolerance in Parkinson's disease: lack of a dose effect.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Nondopaminergic mechanisms in levodopa-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0222

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0222

1 reference

15 August 2017

1 reference